Valproic acid
( DrugBank: - / KEGG DRUG: - )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 5 |
| 5 | Progressive supranuclear palsy | 1 |
| 26 | HTLV-1-associated myelopathy | 2 |
| 65 | Primary immunodeficiency | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 90 | Retinitis pigmentosa | 3 |
| 222 | Primary nephrotic syndrome | 1 |
| 256 | Muscle glycogenosis | 0 |
3. Spinal muscular atrophy
Clinical trials : 297 / Drugs : 143 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 82
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
5. Progressive supranuclear palsy
Clinical trials : 93 / Drugs : 97 - (DrugBank : 33) / Drug target genes : 65 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
26. HTLV-1-associated myelopathy
Clinical trials : 32 / Drugs : 46 - (DrugBank : 27) / Drug target genes : 35 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
65. Primary immunodeficiency
Clinical trials : 798 / Drugs : 585 - (DrugBank : 118) / Drug target genes : 100 - Drug target pathways : 216
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
90. Retinitis pigmentosa
Clinical trials : 186 / Drugs : 191 - (DrugBank : 52) / Drug target genes : 43 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
222. Primary nephrotic syndrome
Clinical trials : 382 / Drugs : 278 - (DrugBank : 98) / Drug target genes : 73 - Drug target pathways : 197
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
256. Muscle glycogenosis
Clinical trials : 193 / Drugs : 97 - (DrugBank : 28) / Drug target genes : 19 - Drug target pathways : 93
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|